Watch how Lena Biosciences' services de-risk drugs early
In this webinar, Dr. James T. Shoemaker, Chief Science Officer at Lena Biosciences takes a deep dive into drug-induced liver injury (DILI), the biggest cause of safety-related drug withdrawals. He shares how a combination of innovative technologies detects DILI signal and isolates the trigger that leads to toxicity, thus providing actionable intelligence for early drug de-risking.
Highlights:
Highlights:
- High-sensitivity assays probe cellular vulnerabilities to find the toxicity trigger
- The relevance of that signal for early drug de-risking
- Dose-dependent changes in the mechanism of toxicity
- How to interpret early warning signs
- How to exclude patient groups at risk
Services offered with SeedEZ and Perfused Organ Panel products
Our services are also available at ScienceExchange.com and Scientist.com
|
We offer standard cytotoxicity service and proprietary screens to isolate the toxicity trigger, dose-dependent changes in the mechanism of toxicity and active mechanisms for a given dose.
| |||||||
|
The service is offered with a xenobiotic metabolism-competent model to assess the effect of the parent compound and its metabolites. Proprietary assays probe specific mitochondrial functions.
| |||
3D CELL-BASED ASSAYS
|
The assays can be run with primary cells, cell lines and iPSC-derived cells. Our panels of proprietary assays can be deployed to answer specific questions.
|
ORGAN-ON-A-CHIP AND MICROPHYSIOLOGICAL SYSTEM (MPS) SERVICE